Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case-control study

Clinical Infectious Diseases

Volumn 32, Issue 5, 2001, Pages 701-707

  Ho, P L ^a   Tse, W S ^b   Tsang, K W T ^a   Kwok, T K ^a   Ng, T K ^a   Cheng, V C C ^a   Chan, R M T ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; HONG KONG; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NONHUMAN; NURSING HOME; PATIENT CARE; PRIORITY JOURNAL; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; DRUG RESISTANCE, MICROBIAL; FEMALE; HONG KONG; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; PNEUMOCOCCAL INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 0035282390     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/319222     Document Type: Article

References (42)

1. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada: 1997 Results from the SENTRY Antimicrobial Surveillance Program
2. Comparative activity of 27 antimicrobial compounds against 698 Streptococcus pneumoniae isolates originating from 20 European university hospitals
3. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
4. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study
5. Antimicrobial resistance of Streptococcus pneumoniae isolated in Taiwan: An island-wide surveillance study between 1996 and 1997
6. Community-acquired pneumonia in adults: Guidelines for management
7. New uses for new and old quinolones and the challenge of resistance
8. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
9. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
10. Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae
11. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
12. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
13. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomised, parallel, multicentre study
14. Antibiotic resistance in Streptococcuspneumoniae
15. Role of infection in chronic bronchitis
16. Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections
17. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients
18. Levofloxacin: Penetration into sputum and once-daily treatment of respiratory tract infections
19. Sparfloxacin vs. ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: A multicenter, double-blind, randomized, comparative study
20. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: The relationship with in-vitro activity
21. Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis
22. Randomized, double-blind study of grepafloxacin versus amoxicillin in patients with acute bacterial exacerbations of chronic bronchitis
23. Treatment of acute exacerbations of chronic bronchitis: Comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study
24. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis
25. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
26. Randomized, double-blind study of ciprofloxacin and cefuroxime axeti] for treatment of acute bacteria] exacerbations of chronic bronchitis
27. Safety and efficacy of oral levofioxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis
28. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis
29. Hospital-related outbreak of infection with multidrug-resistant Streptococcus pneumoniae in The Netherlands
30. Characterization of fiuoroquinolone-resistant Streptococcus pneumoniae in Hong Kong
31. C]inical and economic evaluation of ora] ciprofloxacin after an abbreviated course of intravenous antibiotics
32. Comparative studywith enoxacin and neti]micin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
33. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
34. Concentrations oflevofioxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy
35. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
36. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: Comparison with ciprofloxacin, sparfloxacin, and ofloxacin
37. Penicillin-resistant Streptococcus pneumoniae: An international molecular epidemiology study
38. In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance
39. A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae
40. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid
41. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine